High Tower Advisors, LLC Summit Therapeutics Inc. Transaction History
High Tower Advisors, LLC
- $68.3 Billion
- Q3 2024
A detailed history of High Tower Advisors, LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 39,157 shares of SMMT stock, worth $859,496. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,157
Previous 39,050
0.27%
Holding current value
$859,496
Previous $304,000
181.91%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding SMMT
# of Institutions
201Shares Held
76.4MCall Options Held
2.01MPut Options Held
2.83M-
Baker Bros. Advisors LP New York, NY24.4MShares$536 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$240 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$173 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$119 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$76.1 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.42B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...